 They found that as a class, SGLT2 inhibitors in GLP-1 receptor agonists reduced all-cause mortality and major adverse cardiovascular events compared to other treatments. When they compared specific combinations such as sulfonylureas and insulin with the newer medications, SGLT2s and GLP-1s, for a side effect of interest, severe hypoglycemia, they found that these newer medications also significantly reduced hypoglycemia. Not unexpected.